Iranian President Masoud Pezeshkian announced Wednesday that Tehran is prepared for any verification of its nuclear program, as renewed talks with the U.S. continue amid internal unrest. Speaking at Azadi Square in Tehran, Pezeshkian reiterated that Iran is not seeking atomic weapons, according to Euronews.
The announcement came as the FDA refused to review Moderna's application for an mRNA flu vaccine, a move that the company said blindsided them, according to Ars Technica. This decision is the latest in a series of actions taken by the agency, which is overseen by Robert F. Kennedy Jr., who has been vocal about his anti-vaccine stance. Kennedy has already reduced childhood vaccine recommendations and canceled significant research funding for mRNA vaccines.
In other news, SpaceX's upgraded Super Heavy booster completed cryogenic proof testing, a crucial step before its next Starship flight, Ars Technica reported. The multi-day test, conducted at Starbase, Texas, evaluated the booster's redesigned propellant systems and structural integrity. The 237-foot-tall booster was transported to Masseys Test Site for the testing.
Meanwhile, the National Cancer Institute is using federal funds to study whether the deworming drug ivermectin can cure cancer, according to Ars Technica. This decision has drawn criticism, as large clinical trials have concluded that ivermectin is ineffective against COVID-19, and there is no scientific evidence to support its use in cancer treatment. This study is being conducted under the direction of Health Secretary Robert F. Kennedy Jr.
In the tech sector, major AI industry rivals are collaborating on a new startup accelerator program in Europe, Wired reported. The program, named Fai, will be run by Paris-based incubator Station F and includes partnerships with Meta, Microsoft, Google, Anthropic, OpenAI, and Mistral. The accelerator will provide early-stage startups with classes, lectures, specialist consultations, and introductions to investors.
Discussion
AI Experts & Community
Be the first to comment